CIK 0001689375 · Accelerated filer<br>Smaller reporting company<br>Emerging growth company
Entrada Therapeutics, Inc.
Sign in to watch- Ticker
- TRDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813983399
- Phone
- 857-305-1825
- Business address
- ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON, MA, 02210
- Former names
- CycloPorters, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,200,939
- in 8 filings
Net −$7,200,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-02 | WENTWORTH KORY JAMES Chief Financial Officer | Shares withheld for taxes | −2,939 | $11.66 | $34K | 151,687 |
| 2026-03-02 | Doshi Dipal CEO | Shares withheld for taxes | −9,869 | $11.66 | $115K | 545,195 |
| 2026-03-01 | Sethuraman Natarajan President, Research & Develop. | Grant or award | +55,800 | 253,699 | ||
| 2026-03-01 | Sethuraman Natarajan President, Research & Develop. | Grant or award · Stock Option (Right to Buy) | +83,200 | 83,200 | ||
| 2026-03-01 | Dowden Nathan J President & COO | Grant or award | +55,800 | 234,859 | ||
| 2026-03-01 | Dowden Nathan J President & COO | Grant or award · Stock Option (Right to Buy) | +83,200 | 83,200 | ||
| 2026-03-01 | WENTWORTH KORY JAMES Chief Financial Officer | Grant or award | +44,600 | 154,626 | ||
| 2026-03-01 | WENTWORTH KORY JAMES Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +66,600 | 66,600 | ||
| 2026-03-01 | Doshi Dipal CEO | Grant or award | +139,400 | 555,064 | ||
| 2026-03-01 | Doshi Dipal CEO | Grant or award · Stock Option (Right to Buy) | +208,000 | 208,000 | ||
| 2025-11-21 | WENTWORTH KORY JAMES Chief Financial Officer | Sale 10b5-1 | −8,910 | $9.98 | $89K | 110,026 |
| 2025-11-20 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +1,213 | $9.07 | $11K | 380,152 |
| 2025-11-20 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +13,386 | $9.07 | $121K | 4,678,310 |
| 2025-11-20 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +1,186 | $9.07 | $11K | 381,338 |
| 2025-11-20 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +13,082 | $9.07 | $119K | 4,691,392 |
| 2025-11-14 | PARMAR KUSH Director | Sale | −200,000 | $8.80 | $1.8M | 2,963,066 |
| 2025-11-14 | 5AM Ventures V, L.P. 10% owner | Sale | −200,000 | $8.80 | $1.8M | 2,963,066 |
| 2025-11-12 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +7,321 | $7.73 | $57K | 377,899 |
| 2025-11-12 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +80,881 | $7.73 | $625K | 4,653,430 |
| 2025-11-12 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +1,040 | $7.95 | $8K | 378,939 |
Page 4 of 12 · 230 trades